Additively manufactured medical products - the FDA perspective.
- Published in:
- 3D Printing in Medicine, 2016, v. 2, n. 1, p. 1, doi. 10.1186/s41205-016-0005-9
- By:
- Publication type:
- Article
Works matching DE "UNITED States. Center for Drug Evaluation %26 Research"
Results: 8
1
2
Regulatory watch: Innovation in biologic new molecular entities: 1986-2014.
- Published in:
- Nature Reviews Drug Discovery, 2015, v. 14, n. 2, p. 83, doi. 10.1038/nrd4535
- By:
- Publication type:
- Article
3
FDA REFINES INSPECTION PROCESS FOR CLINICAL SITES.
- Published in:
- Applied Clinical Trials, 2017, v. 26, n. 4/5, p. 18
- By:
- Publication type:
- Article
4
FDA PROMOTES DIVERSITY IN CLINICAL TRIALS.
- Published in:
- Applied Clinical Trials, 2017, v. 26, n. 4/5, p. 15
- By:
- Publication type:
- Article
5
CDER Gains Permanent Chief.
- Published in:
- Applied Clinical Trials, 2008, v. 17, n. 4, p. 22
- By:
- Publication type:
- Article
6
Preparation and characterization of standard reference material 3276, carrot extract in oil.
- Published in:
- Analytical & Bioanalytical Chemistry, 2007, v. 389, n. 1, p. 207, doi. 10.1007/s00216-007-1278-z
- By:
- Publication type:
- Article
7
Metabolomics data and the biomarker qualification process.
- Published in:
- Metabolomics, 2012, v. 8, n. 1, p. 2, doi. 10.1007/s11306-011-0342-z
- By:
- Publication type:
- Article
8
Transition from the lab to the clinic -- Regulatory considerations.
- Published in:
- Journal of Commercial Biotechnology, 2012, v. 18, n. 2, p. 24, doi. 10.5912/jcb506
- By:
- Publication type:
- Article